Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (otvara se novi prozor)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Izvor‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indeks‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (otvara se novi prozor)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (otvara se novi prozor)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Izvor‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indeks‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (otvara se novi prozor)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (otvara se novi prozor)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Izvor‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indeks‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (otvara se novi prozor)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (otvara se novi prozor)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Izvor‎: Blood 2003;102(4):1529-30.

Indeks‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (otvara se novi prozor)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (otvara se novi prozor)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Izvor‎: Transfusion 2007;47(10):1830-6.

Indeks‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (otvara se novi prozor)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (otvara se novi prozor)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Izvor‎: Iran J Blood Cancer 2009;1(4):147-50.

Indeks‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (otvara se novi prozor)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (otvara se novi prozor)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Izvor‎: Int J Hematol 2012;95(1):51-6.

Indeks‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (otvara se novi prozor)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (otvara se novi prozor)

Perrine SP.

Izvor‎: Pediatr Ann 2008;37(5):339-46.

Indeks‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (otvara se novi prozor)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (otvara se novi prozor)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Izvor‎: Sci Rep. 2022;12(1):2752.

Indeks‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (otvara se novi prozor)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (otvara se novi prozor)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Izvor‎: Haematologica 2004;89(10):1172-8.

Indeks‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (otvara se novi prozor)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (otvara se novi prozor)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Izvor‎: Arch Iran Med 2009;12(3):295-7.

Indeks‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (otvara se novi prozor)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (otvara se novi prozor)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Izvor‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indeks‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (otvara se novi prozor)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (otvara se novi prozor)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Izvor‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indeks‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (otvara se novi prozor)

Fetal globin gene inducers: novel agents and new potential. (otvara se novi prozor)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Izvor‎: Ann N Y Acad Sci 2010;1202:158-64.

Indeks‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (otvara se novi prozor)